NCT06277050View on ClinicalTrials.gov

Maintenance Therapy With Toripalimab and Capecitabine Versus Capecitabine Alone in High-risk Nasopharyngeal Carcinoma

PHASE3RecruitingINTERVENTIONAL
Enrollment

264

Participants

Timeline

Start Date

March 7, 2024

Primary Completion Date

February 20, 2029

Study Completion Date

February 20, 2030

Conditions
Nasopharyngeal CarcinomaHigh-Risk CancerMaintenance Therapy
Interventions
DRUG

Maintenance Therapy with Toripalimab and Capecitabine

Capecitabine maintenance therapy (1000 mg/m2 orally twice daily on days 1-14) every 3 weeks. Maintenance therapy of Toripalimab (240 mg, every 3 weeks). The total treatment time of oral chemotherapy is 12 months.

DRUG

Maintenance Therapy with Capecitabine

Capecitabine maintenance therapy (1000 mg/m2 orally twice daily on days 1-14) every 3 weeks. The total treatment time of oral chemotherapy is 12 months.

Trial Locations (3)

330029

RECRUITING

Department of Nasopharyngeal Carcinoma, Jiangxi Cancer Hospital, Nanchang

341000

NOT_YET_RECRUITING

Ganzhou Cancer Hospital, Ganzhou

RECRUITING

First Affiliated hospital of Gannan Medical University, Guangzhou

All Listed Sponsors
lead

Jiangxi Provincial Cancer Hospital

OTHER